… In conclusion, erlotinib prolonged survival and has shown activity as monotherapy following
the … Despite the retrospective design and the small number of patients included, this study …

… study was significantly longer with erlotinib than with placebo in … Oral erlotinib as maintenance
therapy was generally well … that observed in a trial of erlotinib monotherapy as second-line …

… Erlotinib was administered at a dose of 150 mg/d orally until disease progression or
intolerable toxicity. Analysis of epidermal growth factor receptor gene mutations in exon 18–21 by …

… rate to pemetrexed or docetaxel monotherapy as second-line … rate was observed with erlotinib
monotherapy in NSCLC patients… gefitinib has more tolerable toxicity profiles than erlotinib. …

… lower toxicity compared with docetaxel (14). In the case of erlotinib-naïve subjects, erlotinib
is … However, the efficacy of erlotinib as third-line chemotherapy for Japanese patients without …

… Erlotinib is a human epidermal growth factor receptor Type 1/EGFR tyrosine kinase inhibitor.
Erlotinib monotherapy … The most common toxicities associated with erlotinib in phase I trials …

… Compared to the high response rate and long PFS, unexpected erlotinib-related toxicities
were few and mild in degree, and no patient died of treatment related AEs in our study. Due to …

… toxicities. For skin disorders, patients who recovered from grade 2 toxicities could restart
erlotinib … improved from grade 3 to grade 1 skin disorders, the dose was reduced to 100 mg/day. …

… poor performance status (PS) and toxicity during chemotherapy is controversial. We examined
this for erlotinib monotherapy in non-small … erlotinib-related toxicity in the present study. …

… in combination with intravenous bevacizumab 15 mg/kg every 21 days (n = 75) until
disease progression or unacceptable toxicity. OS was analyzed using an unstratified Cox …